



## INCLUSION OF FIRST PATIENTS IN CLINICAL TRIAL IN BRAZIL ON NANOMANGANESE FOR THE TREATMENT OF SEVERE FORMS OF COVID-19

Montpellier, February 07, 2022 at 5:45 p.m. - **Medesis Pharma (ISIN: FR0010844464, MNEMO: ALMDP)**, a **pharmaceutical biotechnology company developing drug candidates with Aonys, its proprietary technology for the delivery of active ingredients in nano micelles by buccal route**, announces the inclusion of the first patients in the phase 2 clinical trial ongoing in Brazil with its drug candidate NanoManganese for the treatment of severe forms of COVID-19.

120 patients will be included in this study carried out in 8 Hospital Centers in Brazil. Treatment with NanoManganese is initiated in hospitalized patients positive for COVID-19. The objective is to quickly improve respiratory symptoms triggered by the SARS-Cov-2 virus, avoiding acute respiratory distress syndrome, evolution towards intensive care and associated complications. The study is double blinded with 90 treated patients and 30 placebos.

NanoManganese associates Aonys® technology with manganese ion, delivering intracellularly manganese at cation state. Manganese Superoxydismutase (MnSOD) is key in mechanisms eliminating intracellular free radicals and has a regulatory role in the immune system. Several studies (*Tanaka 2017, Semrau 1998, Dalpke 2003*) have shown that certain viruses produce autoantibodies directed against MnSOD, inhibiting the enzyme causing an immune system runaway and aggravation of tissue damage, particularly in the lungs. NanoManganese, through its MnSOD-like activity, is thought to balance oxidative stress and downregulate cytokine storm, thus limiting complications observed in patients with severe forms of COVID-19.

The number of cases of COVID-19 in Brazil has increased since the beginning of 2022. The need to find treatments that can limit serious forms of the infection remains a priority. The results of this clinical study should be known during the summer of 2022. Confirmation of the benefit of NanoManganese in this patient population would be a key milestone in the development program of NanoManganese for the treatment of severe forms of aggressive viral diseases (such as COVID-19 or seasonal influenza, etc....).

### About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the buccal administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB). This innovative approach is being applied for future drugs to treat major diseases that do not have effective treatments: Alzheimer’s Disease, Huntington’s Disease, certain resistant cancers and severe respiratory inflammations such as those linked to COVID-19. Medesis Pharma is also developing dedicated treatments for people irradiated following a civil or military nuclear accident.

Medesis Pharma, a French biopharmaceutical company based near Montpellier, has a track record of 15 scientific publications, holds 11 international patents, reflecting 17 years of research, and is focused specifically on four projects that are moving into Clinical Phase II for neurodegenerative diseases and the treatment of Covid-19. Building on its world-renowned positions, Medesis Pharma is also working on new applications for its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major teaching hospital centers in France, Canada and the United States, as well as private structures such as Transgene

Medesis Pharma’s shares are listed on Euronext Growth Paris (FR0010844464 – ALMDP).

### For more information:

[www.medesispharma.com](http://www.medesispharma.com)

### MEDESIS PHARMA

Tessa Olivato  
Tel: +33 4 67 03 03 96  
[contact@medesispharma.com](mailto:contact@medesispharma.com)

### CALYPTUS

Marie Calleux  
Tel : +33 1 53 65 68 66  
[medesispharma@calyptus.net](mailto:medesispharma@calyptus.net)